US-based Ritter Pharmaceuticals has reported positive additional results from a Phase IIb/III trial of its product candidate RP-G28 in patients suffering from lactose intolerance (LI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Lactose is a sugar present in milk and related products, while RP-G28 is non-digestible oligosaccharide currently being developed to regulate gastrointestinal (GI) tract bacteria to metabolise lactose for improved tolerance.

According to the results, RP-G28 showed a clear drug effect with a significant and clinically meaningful reduction in LI symptoms as assessed by different global and real world outcome measures.

Ritter Pharmaceuticals president and co-founder Andrew Ritter said: “As we continue to evaluate the results of this trial, we are increasingly excited by the strength of the data supporting RP-G28’s potentially significant and durable real-world treatment effect for patients suffering from lactose intolerance.”

During the multi-centre, randomised, doubled-blind, placebo-controlled, parallel-group Phase IIb/III trial, the efficacy, safety and tolerability of RP-G28 were evaluated in 377 subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial comprised a 30-day treatment phase and a post-treatment real-world observation phase of additional 30 days, during which subjects consumed lactose containing food products.

"We are increasingly excited by the strength of the data supporting RP-G28’s potentially significant and durable real-world treatment effect for patients suffering from lactose intolerance."

With a composite primary endpoint of abdominal pain, cramping, bloating and gas movement, the trial monitored post-treatment LI symptoms using a Likert scale.

After the re-introduction of dairy and milk products into subjects’ diets, 83% reported LI symptoms relief and 82% experienced no or mild symptom severity.

Furthermore, RP-G28 was found to be safe without any serious adverse events related to the treatment.

Ritter intends to initiate a Phase III programme for RP-G28 in the first half of next year and has already started manufacturing efforts.

Image: Lactose is found in milk and dairy products. Photo: courtesy of World's Direction/flickr.